Introduction
NOMID/CINCA is the most severe phenotype of cryopyrin-associated periodic syndrome (CAPS), characterized by persistence of inflammation-mediated symptoms and overproduction of interleukin (IL)-1β, associated with significant morbidity, if untreated. In CAPS-patients early initiation of anti-IL1β-treatment appears to prevent severe disease sequelae. However, canakinumab as a 1 st -line treatment in young infants suffering from NOMID has been scarcely reported.
Objectives
To report the effects of early-onset canakinumab-treatment in NOMID/CINCA.
Patients and methods
Case presentation.
Results
A late-preterm (37-weeks-gestational-age) girl presented fever, urticarial-like rash, perilimbal redness, meningitis, elevation of WBC/neutrophils, ESR, CRP on 20 hours of life and severe anemia necessitating RBC-transfusion in the 5 th day of life. NOMID/CINCA was suspected on the basis of persistence of elevated inflammatory (including SAA) markers in the absence of infection-causative organisms in blood, CSF and urine, of non-responsiveness to antibiotics, of persistent CNS inflammation (CSF pleiocytosis and elevated protein) and of neutrophilic infiltration (revealed by skin biopsy) in the areas of urticarial-like rash. The detection of the c.1792A>T (p.Ile598Phe) mutation (de-novo as it was no detected in parents) in exon 3 of the NLRP3-gene, causative for NOMID/CINCA according to the infevers-database, confirmed the diagnosis. Brain-MRI was normal despite persistent CNSinflammation represented by pleiocytosis and elevated protein and IL-6 and IL-8-levels in CSF (lumbar puncture performed on the 1 st -day and 3 rd -month of life). In peripheral blood IL-1β, IL-6 and IL-8 were undetectable. Opthalmoscopy/fundoscopy, and auditory-evoked-potentials were normal. After providing immunizations anti-IL1βtreatment with canakinumab 4mg/kg/8 weeks was initiated in the age of 4-months. Fever and rash remitted in 24h. Inflammatory markers normalized after 5-days. On 16-months of age the disease remains into remission. The only sign that persists is perilimbal redness. Mental and motor development is normal. No sensorineural or skeletal manifestations developed. Self-limited, 24h-duration, scarce urticarial-rash appeared in the age of 6 and 15 months with concomitant mild elevation of WBC/ neutrophils and SAA but normal CRP and ESR levels. Repeat MRI revealed absence of CNS involvement and lumbar puncture was not repeated. No adverse reactions presented apart from 1 URI after 12-months of canakinumab treatment.
Conclusion
Early initiation of canakinumab-treatment in CINCA leads to disease-remission and appears to prevent the development severe disease-sequelae such as CNS, sensorineural and skeletal manifestations. The patient presented no severe adverse reactions. 
